+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Growth Hormone Deficiency (GHD) - Epidemiology Forecast to 2032 - Product Thumbnail Image

Growth Hormone Deficiency (GHD) - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Hyperparathyroidism - Epidemiology Forecast to 2032 - Product Thumbnail Image

Hyperparathyroidism - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
HIV-associated Lipodystrophy - Epidemiology Forecast to 2032 - Product Thumbnail Image

HIV-associated Lipodystrophy - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
GM1 Gangliosidosis - Epidemiology Forecast to 2032 - Product Thumbnail Image

GM1 Gangliosidosis - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Adrenal Insufficiency - Epidemiology Forecast to 2032 - Product Thumbnail Image

Adrenal Insufficiency - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
NGLY1 Deficiency - Epidemiology Forecast - 2032 - Product Thumbnail Image

NGLY1 Deficiency - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
Alpha-Mannosidosis - Epidemiology Forecast - 2032 - Product Thumbnail Image

Alpha-Mannosidosis - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Amyloidosis - Epidemiology Forecast - 2032 - Product Thumbnail Image

Amyloidosis - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Androgen Insensitivity Syndrome - Epidemiology Forecast - 2032 - Product Thumbnail Image

Androgen Insensitivity Syndrome - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Cerebrotendinous Xanthomatosis - Epidemiology Forecast - 2032 - Product Thumbnail Image

Cerebrotendinous Xanthomatosis - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
Diabetes - Epidemiology Forecast - 2032 - Product Thumbnail Image

Diabetes - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Diabetic Cardiomyopathy - Epidemiology Forecast - 2032 - Product Thumbnail Image

Diabetic Cardiomyopathy - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more